Sernova (TSE:SVA)
TSX:SVA
Want to see TSE:SVA full AI Analyst Report?
SVA Stock Chart & Stats
C$0.15
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.15
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.12 - C$0.23
Previous CloseN/A
Volume71.45K
Average Volume (3M)125.66K
Market Cap
C$60.16M
Enterprise ValueC$76.09M
Total Cash (Recent Filing)C$576.22K
Total Debt (Recent Filing)C$17.55M
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Jun 12, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding347,726,350
10 Day Avg. Volume126,270
30 Day Avg. Volume125,661
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$300.50K
Bulls Say, Bears Say
Bulls Say
Proprietary Therapeutic PlatformSernova’s Cell Pouch System is a differentiated, implantable platform that creates a vascularized tissue environment to host therapeutic cells (e.g., insulin-producing). As a reusable delivery scaffold, it offers a durable competitive edge across multiple chronic diseases if clinical validation continues, enabling a platform strategy and potential multi-indication commercialization runway.
Moderating Cash Burn TrendOperating cash outflow has declined versus prior years, a meaningful structural improvement for a pre-revenue biotech. Sustained moderation of cash burn extends the funding runway, reduces near-term refinancing pressure, and gives management more time to advance clinical milestones—improving chances of reaching value-creating inflection points without immediate dilutive capital raises.
Improving Loss TrajectorySequentially smaller net losses indicate progress toward cost control and operational efficiency. For a clinical-stage company, a sustained reduction in losses while advancing programs reflects disciplined resource allocation and can preserve capital, improving the company’s ability to fund pivotal studies or negotiate partnerships on stronger footing over the medium term.
Bears Say
Pre-revenue OperationsSernova remains pre-revenue with no commercial inflows, meaning long-term viability depends entirely on successful clinical outcomes and external financing. Absence of product revenue delays self-sustaining cash generation, increasing reliance on markets or partners and elevating execution risk over the next 2–6 months if clinical milestones are not achieved.
Elevated Balance-sheet RiskDeeply negative equity combined with materially higher debt (~$17.5M TTM) constrains financial flexibility and raises solvency concerns. This structural leverage limits ability to absorb setbacks, increases refinancing risk, and makes future capital raises more dilutive or costly, weakening the balance sheet durability required for lengthy clinical development timelines.
Persistent Negative Cash GenerationConsistently negative operating and free cash flows underscore ongoing cash burn and the need for external funding. Even with moderation, continued negative cash generation and very small total assets mean the company faces a structural funding gap that can force dilutive financings or delay programs, which would materially affect long-term value creation.
Sernova News
SVA FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was C$0.12 and its highest was C$0.23 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is C$60.16M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Jun 12, 2026 which is in 45 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Mar 13, 2026. The company reported -C$0.01 earnings per share for the quarter, the consensus estimate of -C$0.01 by C$0.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Overvalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is -0.01.
How many shares outstanding does Sernova have?
Sernova has 347,726,350 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.01 in its last earnings report, expectations of -C$0.01. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―
Options Prices
Currently, No data available
---